Hollande Clémence, Parlati Lucia, Pol Stanislas
Département d'Hépatologie, Université Paris Centre, Hôpital Cochin, APHP, INSERM U1223, Institut Pasteur, Paris, France.
Liver Int. 2020 Feb;40 Suppl 1:67-71. doi: 10.1111/liv.14363.
BACKGROUND & AIMS: HCV affects about 71 million people worldwide with 1.75 million new infections a year, mainly associated with healthcare, blood transfusion before screening of donors and drug use. Hepatitis C is a systemic disease with hepatic and extrahepatic manifestations resulting in increased morbidity and mortality in HCV-infected patients compared to cured or uninfected individuals.
The goal of eliminating hepatitis C by 2030 is based on the following three main actions: strengthening and increasing outreach screening; increasing access to treatment; and improving prevention. Although the tools and the targets of HCV elimination have now been well established, micro-elimination, a cure in high-risk populations, is possible, but has not been achieved. These populations are mainly migrants, prisoners, drug users, HIV co-infected patients and psychiatric patients. New tools must be developed to achieve micro-elimination, in particular, rapid diagnostic orientation tests for better screening, delocalization of healthcare services to improve access to care, and training physicians to raise awareness of the disease, increase understanding of its pathogenesis and provide information on the availability of safe and effective treatment to cure chronic infection and reverse hepatic and extrahepatic manifestations.
Thus, while the goal of complete elimination of hepatitis C virus was feasible in Western countries, it was more difficult in high-prevalence countries where improvement in the detection of chronic infection (with rapid serological and virological diagnostic tests), outsourcing of diagnostic and therapeutic care and access to direct oral antivirals are urgently needed.
丙型肝炎病毒(HCV)在全球约影响7100万人,每年有175万新感染病例,主要与医疗保健、献血者筛查前的输血及药物使用有关。丙型肝炎是一种全身性疾病,有肝脏和肝外表现,与已治愈或未感染个体相比,丙型肝炎病毒感染患者的发病率和死亡率更高。
到2030年消除丙型肝炎的目标基于以下三项主要行动:加强并增加扩大筛查;增加治疗可及性;以及改善预防。尽管消除丙型肝炎病毒的工具和目标现已明确,但在高危人群中实现微观消除(治愈)是可行的,但尚未实现。这些人群主要是移民、囚犯、吸毒者、合并感染艾滋病毒的患者和精神病患者。必须开发新工具以实现微观消除,特别是用于更好筛查的快速诊断定向检测、将医疗服务去中心化以改善医疗可及性,以及培训医生以提高对该疾病的认识、增进对其发病机制的理解,并提供关于安全有效治疗以治愈慢性感染及逆转肝脏和肝外表现的可及性信息。
因此,虽然在西方国家完全消除丙型肝炎病毒的目标是可行的,但在高流行国家则更为困难,在这些国家迫切需要通过快速血清学和病毒学诊断检测改善慢性感染的检测、将诊断和治疗护理外包,以及获取直接口服抗病毒药物。